![]() Saving Earth Britannica Presents Earth’s To-Do List for the 21st Century.100 Women Britannica celebrates the centennial of the Nineteenth Amendment, highlighting suffragists and history-making politicians.COVID-19 Portal While this global health crisis continues to evolve, it can be useful to look to past pandemics to better understand how to respond today.Student Portal Britannica is the ultimate student resource for key school subjects like history, government, literature, and more.This Time in History In these videos, find out what happened this month (or any month!) in history.#WTFact Videos In #WTFact Britannica shares some of the most bizarre facts we can find.Demystified Videos In Demystified, Britannica has all the answers to your burning questions.Britannica Classics Check out these retro videos from Encyclopedia Britannica’s archives.Britannica Explains In these videos, Britannica explains a variety of topics and answers frequently asked questions. What is Annihilation Definition A collision between any particle and its antiparticle partner is known to lead to their mutual annihilation.However, a PFS benefit was found in case of combination therapy, whose clinical meaning is not yet clear.Ībiraterone Androgen annihilation Enzalutamide MCRPC Novel hormonal therapy Overall survival Progression free survival.Ĭopyright © 2022 Elsevier B.V. Optimal treatment sequence and patient selection for androgen annihilation remain open points. This might be ascribed to an increased rate of other cause mortality that might determine the absence of an OS benefit or to the efficacy of second line therapies. ![]() ![]() We found no OS benefit for patients with mCRPC treated with androgen annihilation compared to advanced androgen blockage. Patients receiving androgen annihilation exhibited better PFS compared to advanced androgen blockage: ΔRMST at 36 months of 2.4 months (95%CI: 1.0, 3.8, p = 0.001). At 36 months, relatively to ADT alone, patients receiving androgen annihilation or advanced androgen blockage exhibited longer OS: ΔRMST of 1.6 (95%CI: 0.6, 2.7, p = 0.002) and 1.8 months (95%CI: 1.1, 2.5, p < 0.001), respectively. Overall, patients receiving androgen annihilation exhibited similar OS compared to advanced androgen blockage: ΔRMST at 36 months of - 0.2 (95%CI: -1.1, 0.8, p = 0.8). The term annihilationism is taken from the Greek word, apoleia, which is translated as destruction in 2 Peter 3:7. ![]() Three trials were included involving 3787 patients. The outcomes of interest were assessed using difference in restricted mean survival time (ΔRMST) at different time points. We reconstructed survival data from published Kaplan-Meier curves on overall survival (OS) and progression free survival (PFS) and meta-analyzed androgen annihilation versus advanced androgen blockage (grouping together abiraterone and enzalutamide) versus androgen deprivation therapy. Herein, we performed a meta-analysis to compare overall survival (OS) and progression free survival (PFS) among patients who received androgen annihilation versus advanced androgen blockage (abiraterone or enzalutamide), in addition to conventional androgen deprivation therapy.Ī comprehensive search for all published phase III randomized control trials on first line mCRPC that evaluated advanced androgen blockage (COU-AA-302, PREVAIL) or androgen annihilation (ACIS) was conducted PubMed, EMBASE, Web of Science, and Scopus databases up to. On this matter, the recent ACIS trial tested the role of abiraterone plus apalutamide (androgen annihilation) in addition to androgen deprivation therapy, versus abiraterone plus androgen deprivation therapy. Despite recent advances in the treatments of metastatic castration resistant prostate cancer (mCRPC), patients' prognosis remains suboptimal and novel treatment combinations are under scrutiny. ![]()
0 Comments
Leave a Reply. |